Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00595465 | Comparison of Three Commercial Batches of the Japanese Encephalitis Vaccine IC51 | PHASE3 | COMPLETED | 389 | — | — | Dec 1, 2007 | Jun 1, 2008 | May 16, 2014 | 4 | Austria, Germany |
| Arm | Type | Description |
|---|---|---|
| IC51 Batch A | ACTIVE_COMPARATOR | - |
| IC51 Batch B | ACTIVE_COMPARATOR | - |
| IC51 Batch C | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Japanese Encephalitis purified inactivated vaccine | BIOLOGICAL | IC51 6 mcg i.m. injection on Day 0 and Day 28 |
Main Inclusion Criteria: * Male and female healthy adults aged at least 18 years, with written informed consent and either no childbearing potential or negative pregnancy test Main Exclusion Criteria: * History of immunodeficiency or immunosuppressive therapy, * Known Human Immunodeficiency Virus...